| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Epidemiologic classification of human papillomavirus types associated with cervical cancer.
|
N Engl J Med
|
2003
|
31.67
|
|
2
|
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners.
|
N Engl J Med
|
2002
|
10.80
|
|
3
|
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
|
Lancet Oncol
|
2010
|
9.86
|
|
4
|
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
|
Lancet
|
2007
|
8.55
|
|
5
|
Against which human papillomavirus types shall we vaccinate and screen? The international perspective.
|
Int J Cancer
|
2004
|
6.99
|
|
6
|
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.
|
Lancet Infect Dis
|
2007
|
6.86
|
|
7
|
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.
|
J Natl Cancer Inst
|
2003
|
6.28
|
|
8
|
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
|
Lancet Oncol
|
2011
|
5.57
|
|
9
|
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
|
J Infect Dis
|
2009
|
5.09
|
|
10
|
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study.
|
Lancet
|
2002
|
5.00
|
|
11
|
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials.
|
Lancet Oncol
|
2015
|
4.84
|
|
12
|
Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings.
|
J Infect Dis
|
2010
|
4.42
|
|
13
|
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
|
J Natl Cancer Inst
|
2010
|
4.20
|
|
14
|
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.
|
J Natl Cancer Inst
|
2006
|
4.14
|
|
15
|
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium.
|
Lancet Oncol
|
2006
|
4.13
|
|
16
|
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
|
Lancet Oncol
|
2011
|
3.98
|
|
17
|
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study.
|
Lancet
|
2002
|
3.96
|
|
18
|
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
|
Int J Cancer
|
2009
|
3.64
|
|
19
|
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.
|
J Infect Dis
|
2009
|
3.55
|
|
20
|
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
|
BMJ
|
2010
|
3.41
|
|
21
|
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide.
|
Int J Cancer
|
2006
|
3.38
|
|
22
|
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
|
J Natl Cancer Inst
|
2004
|
3.11
|
|
23
|
Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer.
|
J Natl Cancer Inst
|
2002
|
2.75
|
|
24
|
Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies.
|
Lancet Oncol
|
2011
|
2.52
|
|
25
|
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
|
Cancer Prev Res (Phila)
|
2009
|
2.42
|
|
26
|
Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.
|
Vaccine
|
2008
|
2.13
|
|
27
|
Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study.
|
Cancer Causes Control
|
2003
|
2.00
|
|
28
|
Cervical human papillomavirus infection in the female population in Barcelona, Spain.
|
Sex Transm Dis
|
2003
|
1.93
|
|
29
|
Risk factors of invasive cervical cancer in Mali.
|
Int J Epidemiol
|
2002
|
1.74
|
|
30
|
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial.
|
Gynecol Oncol
|
2012
|
1.70
|
|
31
|
Environmental co-factors in HPV carcinogenesis.
|
Virus Res
|
2002
|
1.66
|
|
32
|
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.
|
Hum Vaccin
|
2009
|
1.66
|
|
33
|
The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis.
|
Int J Cancer
|
2004
|
1.63
|
|
34
|
The Strong Protective Effect of Circumcision against Cancer of the Penis.
|
Adv Urol
|
2011
|
1.63
|
|
35
|
Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study.
|
Int J Cancer
|
2004
|
1.62
|
|
36
|
HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
|
Gynecol Oncol
|
2009
|
1.48
|
|
37
|
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva.
|
Eur J Cancer
|
2013
|
1.42
|
|
38
|
Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population.
|
J Clin Microbiol
|
2004
|
1.34
|
|
39
|
Chlamydia trachomatis infection in female partners of circumcised and uncircumcised adult men.
|
Am J Epidemiol
|
2005
|
1.33
|
|
40
|
Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines.
|
J Infect Dis
|
2002
|
1.32
|
|
41
|
Prevalence of Kaposi's sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain.
|
Int J Cancer
|
2002
|
1.27
|
|
42
|
Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion.
|
Cancer Res
|
2005
|
1.23
|
|
43
|
Cervical cancer control, priorities and new directions.
|
Int J Cancer
|
2004
|
1.23
|
|
44
|
Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16.
|
J Virol
|
2005
|
1.22
|
|
45
|
Human Papillomavirus (HPV) infection in pregnant women and mother-to-child transmission of genital HPV genotypes: a prospective study in Spain.
|
BMC Infect Dis
|
2009
|
1.15
|
|
46
|
HPV and circumcision: a biased, inaccurate and misleading meta-analysis.
|
J Infect
|
2007
|
1.15
|
|
47
|
Can screening for cervical cancer be improved, especially in developing countries?
|
Int J Cancer
|
2003
|
1.14
|
|
48
|
Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study.
|
Int J Cancer
|
2003
|
1.10
|
|
49
|
The male role in cervical cancer.
|
Salud Publica Mex
|
2003
|
1.07
|
|
50
|
Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18.
|
Virology
|
2005
|
1.06
|
|
51
|
Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention.
|
Int J Cancer
|
2008
|
1.05
|
|
52
|
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.
|
PLoS One
|
2013
|
1.04
|
|
53
|
Recommendations for cervical cancer prevention in Asia Pacific.
|
Vaccine
|
2008
|
1.04
|
|
54
|
Prevalence and risk factors of sexually transmitted infections and cervical neoplasia in women from a rural area of southern Mozambique.
|
Infect Dis Obstet Gynecol
|
2010
|
1.03
|
|
55
|
Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.
|
Vaccine
|
2008
|
1.03
|
|
56
|
Age at sexual initiation and number of sexual partners in the female Spanish population Results from the AFRODITA survey.
|
Eur J Obstet Gynecol Reprod Biol
|
2008
|
0.97
|
|
57
|
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine.
|
Int J Cancer
|
2011
|
0.95
|
|
58
|
Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array.
|
Infect Agent Cancer
|
2011
|
0.95
|
|
59
|
Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study.
|
J Med Virol
|
2012
|
0.95
|
|
60
|
Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort.
|
Int J Cancer
|
2014
|
0.94
|
|
61
|
Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts.
|
Vaccine
|
2006
|
0.94
|
|
62
|
The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe.
|
J Hepatol
|
2008
|
0.93
|
|
63
|
Cervical infection with Chlamydia trachomatis and Neisseria gonorrhoeae in women from ten areas in four continents. A cross-sectional study.
|
Sex Transm Dis
|
2007
|
0.93
|
|
64
|
Recommendations for cervical cancer prevention in Latin America and the Caribbean.
|
Vaccine
|
2008
|
0.92
|
|
65
|
Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer.
|
Vaccine
|
2006
|
0.92
|
|
66
|
Human papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa: could HIV explain the differences?
|
Trop Med Int Health
|
2012
|
0.92
|
|
67
|
Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
|
Eur J Cancer
|
2010
|
0.91
|
|
68
|
Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain.
|
J Low Genit Tract Dis
|
2008
|
0.91
|
|
69
|
Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: evidence from the EPIC cohort.
|
Int J Cancer
|
2014
|
0.89
|
|
70
|
The role of human papillomavirus in head and neck cancer in Senegal.
|
Infect Agent Cancer
|
2013
|
0.89
|
|
71
|
Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up.
|
Int J Cancer
|
2006
|
0.89
|
|
72
|
Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy.
|
BMC Cancer
|
2010
|
0.89
|
|
73
|
Aflatoxin, hepatitis and worldwide liver cancer risks.
|
Adv Exp Med Biol
|
2002
|
0.89
|
|
74
|
Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.88
|
|
75
|
Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.
|
Clin Vaccine Immunol
|
2007
|
0.88
|
|
76
|
Dietary factors and in situ and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study.
|
Int J Cancer
|
2010
|
0.88
|
|
77
|
Male circumcision and prevalence of genital human papillomavirus infection in men: a multinational study.
|
BMC Infect Dis
|
2013
|
0.85
|
|
78
|
Using HPV prevalence to predict cervical cancer incidence.
|
Int J Cancer
|
2012
|
0.85
|
|
79
|
Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention.
|
Gynecol Oncol
|
2011
|
0.84
|
|
80
|
Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study.
|
Sex Transm Dis
|
2007
|
0.84
|
|
81
|
Smoking and passive smoking in cervical cancer risk: pooled analysis of couples from the IARC multicentric case-control studies.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.83
|
|
82
|
[Screening history in women with infiltrating uterine cancer].
|
Gac Sanit
|
2006
|
0.83
|
|
83
|
Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE study.
|
BMC Infect Dis
|
2012
|
0.83
|
|
84
|
Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
|
Eur J Public Health
|
2008
|
0.83
|
|
85
|
Male circumcision and the incidence and clearance of genital human papillomavirus (HPV) infection in men: the HPV Infection in men (HIM) cohort study.
|
BMC Infect Dis
|
2014
|
0.82
|
|
86
|
Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
|
BMC Infect Dis
|
2012
|
0.80
|
|
87
|
Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007.
|
Int J Cancer
|
2013
|
0.80
|
|
88
|
Organotypic co-cultures allow for immortalized human gingival keratinocytes to reconstitute a gingival epithelial phenotype in vitro.
|
Differentiation
|
2006
|
0.80
|
|
89
|
Type-specific human papillomavirus distribution in invasive cervical cancer in Korea, 1958-2004.
|
Asian Pac J Cancer Prev
|
2010
|
0.79
|
|
90
|
A scientific response to prevent cervical cancer in the world.
|
Vaccine
|
2008
|
0.78
|
|
91
|
Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis.
|
Eur J Cancer Prev
|
2016
|
0.78
|
|
92
|
Laser capture microdissection shows HPV11 as both a causal and a coincidental infection in cervical cancer specimens with multiple HPV types.
|
Histopathology
|
2013
|
0.78
|
|
93
|
New opportunities for cancer prevention.
|
Vaccine
|
2009
|
0.78
|
|
94
|
Is viral status needed before vaccination?
|
Vaccine
|
2008
|
0.78
|
|
95
|
[Assessment of HPV detection assays for use in cervical cancer screening programs].
|
Salud Publica Mex
|
2006
|
0.77
|
|
96
|
Human papillomavirus vaccines and vaccine implementation.
|
Womens Health (Lond Engl)
|
2008
|
0.77
|
|
97
|
Patient with hepatocellular carcinoma related to prior acute arsenic intoxication and occult HBV: epidemiological, clinical and therapeutic results after 14 years of follow-up.
|
World J Gastroenterol
|
2006
|
0.75
|
|
98
|
Correction: The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort.
|
PLoS One
|
2016
|
0.75
|
|
99
|
Screening for cervical cancer and human papillomavirus vaccination in Israel: recommendations.
|
Vaccine
|
2013
|
0.75
|
|
100
|
HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico.
|
Salud Publica Mex
|
2016
|
0.75
|
|
101
|
Time trends in incidence and mortality for chronic liver disease and liver cancer in the interval 1980-1997 in Catalonia, Spain.
|
Eur J Gastroenterol Hepatol
|
2004
|
0.75
|
|
102
|
Broad-spectrum human papillomavirus vaccines: new horizons but one step at a time.
|
J Natl Cancer Inst
|
2009
|
0.75
|
|
103
|
Eradication of cervical cancer in Latin America.
|
Salud Publica Mex
|
2016
|
0.75
|
|
104
|
Cervical cancer: advances in prevention and knowledge of its etiology.
|
Salud Publica Mex
|
2003
|
0.75
|